AGN-151597 / AbbVie 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   7 News 
  • ||||||||||  AGN-151597 / AbbVie
    Trial completion date, Metastases:  RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa (clinicaltrials.gov) -  Oct 6, 2022   
    P1/2,  N=14, Active, not recruiting, 
    Active, not recruiting --> Completed Trial completion date: Apr 2035 --> Sep 2024
  • ||||||||||  AGN-151597 / AbbVie, GS030 / GenSight
    Journal:  Current and Future Treatment of Retinitis Pigmentosa. (Pubmed Central) -  Sep 11, 2022   
    Gene therapies may be attractive as their fundamental goal is to restore vision; however, cell therapies will likely have a broader application and do not rely on genetic testing, which can delay treatment. Ensuring effective therapeutic options for RP patients across disease stages requires the continued diversification and advancement of the development pipeline, and sustained efforts to promote early patient identification and timely diagnosis.
  • ||||||||||  AGN-151597 / AbbVie
    Trial primary completion date, Metastases:  RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa (clinicaltrials.gov) -  Jan 26, 2021   
    P1/2,  N=14, Active, not recruiting, 
    Ensuring effective therapeutic options for RP patients across disease stages requires the continued diversification and advancement of the development pipeline, and sustained efforts to promote early patient identification and timely diagnosis. Trial primary completion date: Dec 2020 --> Jun 2020
  • ||||||||||  AGN-151597 / AbbVie
    Enrollment closed, Enrollment change, Metastases:  RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa (clinicaltrials.gov) -  Mar 25, 2020   
    P1/2,  N=14, Active, not recruiting, 
    Trial primary completion date: Dec 2020 --> Jun 2020 Recruiting --> Active, not recruiting | N=21 --> 14
  • ||||||||||  AGN-151597 / AbbVie
    Trial completion date, Trial primary completion date, Metastases:  RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa (clinicaltrials.gov) -  Aug 20, 2019   
    P1/2,  N=21, Recruiting, 
    Recruiting --> Active, not recruiting | N=21 --> 14 Trial completion date: Oct 2033 --> Apr 2035 | Trial primary completion date: Aug 2019 --> Dec 2020
  • ||||||||||  AGN-151597 / AbbVie
    Enrollment change, Metastases:  RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa (clinicaltrials.gov) -  Jan 12, 2018   
    P1/2,  N=21, Recruiting, 
    Trial completion date: Oct 2033 --> Apr 2035 | Trial primary completion date: Aug 2019 --> Dec 2020 N=15 --> 21
  • ||||||||||  AGN-151597 / AbbVie
    Trial primary completion date, Metastases:  RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa (clinicaltrials.gov) -  Jul 11, 2017   
    P1/2,  N=15, Recruiting, 
    N=15 --> 21 Trial primary completion date: Apr 2017 --> Aug 2019
  • ||||||||||  AGN-151597 / AbbVie
    Enrollment open, Metastases:  RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa (clinicaltrials.gov) -  Nov 5, 2015   
    P1/2,  N=15, Recruiting, 
    Trial primary completion date: Apr 2017 --> Aug 2019 Not yet recruiting --> Recruiting